Literature DB >> 15388421

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Hanan K Munayyer1, Paul A Mann, Andrew S Chau, Taisa Yarosh-Tomaine, Jonathan R Greene, Roberta S Hare, Larry Heimark, Robert E Palermo, David Loebenberg, Paul M McNicholas.   

Abstract

Posaconazole (POS; SCH 56592) is a novel triazole that is active against a wide variety of fungi, including fluconazole-resistant Candida albicans isolates and fungi that are inherently less susceptible to approved azoles, such as Candida glabrata. In this study, we compared the effects of POS, itraconazole (ITZ), fluconazole (FLZ), and voriconazole (VOR) on sterol biosynthesis in strains of C. albicans (both azole-sensitive and azole-resistant strains), C. glabrata, Aspergillus fumigatus, and Aspergillus flavus. Following exposure to azoles, nonsaponifiable sterols were extracted and resolved by liquid chromatography and sterol identity was confirmed by mass spectroscopy. Ergosterol was the major sterol in all but one of the strains; C. glabrata strain C110 synthesized an unusual sterol in place of ergosterol. Exposure to POS led to a decrease in the total sterol content of all the strains tested. The decrease was accompanied by the accumulation of 14alpha-methylated sterols, supporting the contention that POS inhibits the cytochrome P450 14alpha-demethylase enzyme. The degree of sterol inhibition was dependent on both dose and the susceptibility of the strain tested. POS retained activity against C. albicans isolates with mutated forms of the 14alpha-demethylase that rendered these strains resistant to FLZ, ITZ, and VOR. In addition, POS was a more potent inhibitor of sterol synthesis in A. fumigatus and A. flavus than either ITZ or VOR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388421      PMCID: PMC521889          DOI: 10.1128/AAC.48.10.3690-3696.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

Authors:  E K Manavathu; J L Cutright; D Loebenberg; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Effects of voriconazole on Candida glabrata in vitro.

Authors:  A Koul; J Vitullo; G Reyes; M Ghannoum
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

3.  The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger.

Authors:  P Marichal; J Gorrens; H Vanden Bossche
Journal:  Sabouraudia       Date:  1985-02

4.  Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.

Authors:  W Lamar Smith; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis.

Authors:  Larry Heimark; Petia Shipkova; Jonathan Greene; Hanan Munayyer; Taisa Yarosh-Tomaine; Beth DiDomenico; Roberta Hare; Birendra N Pramanik
Journal:  J Mass Spectrom       Date:  2002-03       Impact factor: 1.982

Review 6.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata.

Authors:  H Nakayama; N Nakayama; M Arisawa; Y Aoki
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.

Authors:  Hilmar Wisplinghoff; Harald Seifert; Sandra M Tallent; Tammy Bischoff; Richard P Wenzel; Michael B Edmond
Journal:  Pediatr Infect Dis J       Date:  2003-08       Impact factor: 2.129

10.  Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Authors:  Andrew S Chau; Cara A Mendrick; Frank J Sabatelli; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more
  24 in total

1.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Detection of posaconazole by surface-assisted laser desorption/ionization mass spectrometry with dispersive liquid-liquid microextraction.

Authors:  Sheng-Yu Lin; Pin-Shiuan Chen; Sarah Y Chang
Journal:  J Am Soc Mass Spectrom       Date:  2015-01-06       Impact factor: 3.109

4.  Synergistic drug combination effectively blocks Ebola virus infection.

Authors:  Wei Sun; Shihua He; Carles Martínez-Romero; Jennifer Kouznetsova; Gregory Tawa; Miao Xu; Paul Shinn; Ethan Fisher; Yan Long; Omid Motabar; Shu Yang; Philip E Sanderson; Peter R Williamson; Adolfo García-Sastre; Xiangguo Qiu; Wei Zheng
Journal:  Antiviral Res       Date:  2016-11-24       Impact factor: 5.970

5.  Erg4A and Erg4B Are Required for Conidiation and Azole Resistance via Regulation of Ergosterol Biosynthesis in Aspergillus fumigatus.

Authors:  Nanbiao Long; Xiaoling Xu; Qiuqiong Zeng; Hong Sang; Ling Lu
Journal:  Appl Environ Microbiol       Date:  2017-02-01       Impact factor: 4.792

6.  Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.

Authors:  Andrew S Chau; Guodong Chen; Paul M McNicholas; Paul A Mann
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

7.  Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

Authors:  Paolo Campoli; David S Perlin; Arnold S Kristof; Theodore C White; Scott G Filler; Donald C Sheppard
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 8.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Authors:  Galina I Lepesheva; Robert D Ott; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Inge Schuster; W David Nes; George C Hill; Fernando Villalta; Michael R Waterman
Journal:  Chem Biol       Date:  2007-11

10.  Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.

Authors:  Guillermo Garcia-Effron; Amanda Dilger; Laura Alcazar-Fuoli; Steven Park; Emilia Mellado; David S Perlin
Journal:  J Clin Microbiol       Date:  2008-01-30       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.